Clinical Trial Update: Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial investigating bendamustine, mitoxantrone, and rituximab (BMR) in untreated high-risk follicular lymphoma; study terminated with results posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Bendamustine, Mitoxantrone, Rituximab (BMR)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Follicular Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2020-04-03